- Home
- AACB vs RIGL Comparison
AACB vs RIGL Comparison
Compare AACB & RIGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AACB
- RIGL
- Stock Information
- Founded
- AACB 2024
- RIGL 1996
- Country
- AACB United States
- RIGL United States
- Employees
- AACB N/A
- RIGL N/A
- Industry
- AACB
- RIGL Biotechnology: Pharmaceutical Preparations
- Sector
- AACB
- RIGL Health Care
- Exchange
- AACB Nasdaq
- RIGL Nasdaq
- Market Cap
- AACB 298.1M
- RIGL 335.5M
- IPO Year
- AACB 2025
- RIGL 2000
- Fundamental
- Price
- AACB $10.14
- RIGL $18.93
- Analyst Decision
- AACB
- RIGL Buy
- Analyst Count
- AACB 0
- RIGL 5
- Target Price
- AACB N/A
- RIGL $36.40
- AVG Volume (30 Days)
- AACB 11.5K
- RIGL 176.2K
- Earning Date
- AACB 01-01-0001
- RIGL 08-05-2025
- Dividend Yield
- AACB N/A
- RIGL N/A
- EPS Growth
- AACB N/A
- RIGL N/A
- EPS
- AACB N/A
- RIGL 2.08
- Revenue
- AACB N/A
- RIGL $203,077,000.00
- Revenue This Year
- AACB N/A
- RIGL $14.41
- Revenue Next Year
- AACB N/A
- RIGL $15.97
- P/E Ratio
- AACB N/A
- RIGL $9.09
- Revenue Growth
- AACB N/A
- RIGL 70.16
- 52 Week Low
- AACB $10.00
- RIGL $7.48
- 52 Week High
- AACB $11.35
- RIGL $29.82
- Technical
- Relative Strength Index (RSI)
- AACB N/A
- RIGL 41.53
- Support Level
- AACB N/A
- RIGL $21.04
- Resistance Level
- AACB N/A
- RIGL $21.51
- Average True Range (ATR)
- AACB 0.00
- RIGL 0.99
- MACD
- AACB 0.00
- RIGL -0.27
- Stochastic Oscillator
- AACB 0.00
- RIGL 2.19
About AACB Artius II Acquisition Inc. Class A Ordinary Shares
Artius II Acquisition Inc is a blank check company.
About RIGL Rigel Pharmaceuticals Inc.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.